Stewart, CF: Pharmacodynamics and dose intensity in cancer. J Pharm Pract4:11-19, 1991
2.
Legha SS, Benjamin RS, MacKay B., et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med96:133-139, 1982
3.
Legha SS, Benjamin RS, MacKay B., et al: Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer49:1762-1766, 1982
4.
Lokich J., Bothe A., Zipoli T., et al: Constant infusion schedule for Adriamycin: A phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system. J Clin Oncol1:24-28, 1983
5.
Garnick MB, Weiss GR, Steele GD Jr, et al: Clinical evaluation of long-term, continuous-infusion doxorubicin . Cancer Treat Rep67:133-142, 1983
6.
Coonley C., Vugrin D., LaMonte C., et al: Bleomycin infusion: Pulmonary toxicity. Proc Am Assn Ca Res andAm Soc Clin Oncol22:369,1981 (abstr)
7.
Cooper KR, Hong WK: Prospective study of the pulmonary toxicity of continuously infused bleomycin , Cancer Treat Rep65:419-425, 1981
8.
Krakoff IH, Cvitkovic E., Currie V., et al: Clinical pharmacology and therapeutic studies of bleomycin given by continuous infusion. Cancer40:2027-2037, 1977
9.
Lemon HM: Reduction of 5-fluorouracil toxicity in man with retention of anticancer effects by prolonged intravenous administration in 5% dextrose. Cancer Chemother Rep8;97-101, 1960
10.
Lokich J., Bothe A., Fine N., et al: Phase I study of protracted venous infusion of 5-fluorouracil . Cancer48:2565-2568,1981
11.
Hickman RO, Buckner CD, Clift RA, et al: A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet148: 871-875, 1979
12.
Ivey MF, Adam SM, Hickman RO, et al: Right atrial indwelling catheter for patients requiring long-term intravenous therapy. Am J Hosp Pharm35:1525-1527, 1978
13.
Fleming CR, Witzke DJ, Beart RW Jr: Catheter-related complications in patients receiving home parenteral nutrition . Ann Surg192:593-599, 1980
14.
Gruber B., Moran WJ, Vokes EE, et al: Implantable venous access device: Use in patients with advanced head and neck cancer. Otolaryngol Head Neck Surg99:578-583, 1990
15.
Plesse T., Ohnuma T., Bruckner H., et al: Portable infusion pumps in ambulatory cancer chemotherapy. Cancer50:27-31,1982
16.
Samuels ML, Johnson DE, Holoye PY: Continuous infusion bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. Cancer Chemother Rep59:563-570,1975
17.
Dreyfuss AI , Clark JR, Wright JE, et al: Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med112:167-172, 1990
18.
Southwest Oncology Group: Cytarabine for acute leukemia in adults: Effects of schedule on therapeutic response. Arch Intern Med133:251-259, 1974
19.
Bodey GP, Coltman CA, Hewlett JS, et al: Progress in the treatment of adults with acute leukemia: Review of regimens containing cytarabine studies by the Southwest Oncology Group . Arch Intern Med136:1383-1388, 1976
20.
Preisler H. , Bjornsson S., Henderson ES, et al: Remission induction in acute nonlymphocytic leukemia: Comparison of a seven-day and ten-day infusion of cytosine arabinoside in combination with adriamycin. Med Pediatr Oncol7:269-275, 1979
21.
Rai KR, Holland JF, Glidewell OJ, et al: Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B. Blood58:1203-1212,1981
22.
Benjamin R. , Yap B., Frazier O. Jr, et al: Combination chemotherapy for sarcomas with cyclophosphamide and continuous infusion adriamycin and dacarbazine (CI-CyADIC) with surgical intensification. Proc Am Assn Ca Res andAm Soc Clin Oncol22:526, 1981 (abstr)
23.
Elias AD, Ryan L., Aisner J., et al: Doxorubicin, ifosfamide, and DTIC (AID) for advanced untreated sarcomas. Proc Am Soc Clin Oncol6:134, 1987 (abstr A-524)
24.
Huffman DH, Benjamin RS, Bachur NR: Daunorubicin metabolism in acute nonlymphocytic leukemia. Clin Pharmacol Ther13:895-905,1972
25.
Barlogie B. , Smith L., Alexanian R.: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med310:1353-1356, 1984
26.
Gore ME, Selby PJ, Millar B., et al: The use of verapamil to overcome drug resistance in myeloma . Proc Am Soc Clin Oncol7:228, 1988 (abstr A-882)
27.
Creagan ET, Richardson RL, Kovach JS: Pilot study of a continuous five-day intravenous infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer. J Clin Oncol6:1197-1201, 1988
28.
Slevin ML, Clark PI, Osborne RJ, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. Proc Am Soc Clin Oncol5:175,1986 (abstr)
29.
Seifert P., Baker LH, Reed ML, et al: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer48:2565-2568, 1975
30.
Caballero GA , Ausman RK, Quebbeman EJ: Long-term ambulatory, continuous infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep69:13-15, 1985
31.
Hartment HA Jr, Kessinger A., Lemon HM, et al: Five-day continuous infusion of 5-fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma. J Surg Oncol11:227-238,1979
32.
Yap HY, Blumenschein GR, Keating MJ, et al: Vinblastine given as continuous five-day infusion in the treatment of refractory, advanced breast cancer. Cancer Treat Rep64:279-283,1980
33.
Aeberhard P. : Intraarterial chemotherapy without pump. AntibiotChemother40:41-50, 1988
34.
Patt YZ: Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer in the liver: Why, how, what? AntibiotChemother40:1-11, 1988
Chen Hsg, Gross JF: Intra-arterial infusion of anticancer drugs: Theoretic aspects of drug delivery and review of responses. Cancer Treat Rep64:31-40, 1980
37.
Wallace S., Charnsangavej C., Carrasco CH, et al: Infusion-embolization. Cancer54:2751-2765,1984
38.
Wolf BE, Sugarbaker PH: Intraperitoneal chemotherapy and immunotherapy. Rec ResultsCancer Res110:254-273,1988
39.
Brenner DE: Intraperitoneal chemotherapy: A review. J Clin Oncol4:1135-1147, 1986
40.
Ozols RF, Locker GY, Doroshow JH, et al: Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res39:3209-3214, 1979
41.
Howell SB: Improving the therapeutic index of intraarterial cisplatin chemotherapy . Eur J Cancer Clin Oncol25:775-776, 1989
42.
Akahoshi Y. , Takeuchi S., Chen S., et al: The results of surgical treatment combined with intra-arterial infusion of anti-cancer agents in osteosarcoma . Clin Orthopaed120:103-109, 1976
43.
Eilber FR, Grant T., Morton DL: Adjuvant therapy for osteosarcoma: Preoperative treatment. Cancer Treat Rep62:213-216, 1978
44.
Jaffe N., Prudich J., Knapp J., et al: Osteosarcoma: Treatment of the primary tumor with intra-arterial high dose methotrexate (MTX-CF): Pharmacokinetic, clinical, radiographic, and pathologic studies. Am AssocCancer Res22:195, 1981 (abstr)
45.
Jaffe N., Bowman R., Wang Y-M., et al: Chemotherapy for primary osteosarcoma by intra-arterial infusion . Cancer Bull36:37-42,1984
46.
Madajewics S. , West C., Avellanos A., et al: Intraarterial chemotherapy for brain metastases. Thirteenth International Congress, Seattle, WA, 13th International Cancer Congress Inc, 1982, p 74
47.
Stewart DJ, Wallace S., Feun LG, et al: A phase I study of intracarotid artery infusion of cisdiamminedichloroplatinum (II) in patients with recurrent malignant intracerebral tumors. Cancer Res42:2059-2062, 1982
48.
Feun LG, Wallace S., Stewart DJ, et al: Phase I-II trial of intracarotid (IC) cis-diamminedichloroplatinum (CPPD) inpatients with intracerebral tumors. Proc Am Soc Clin Oncol1:197, 1982 (abstr)
49.
Feun LG: Intra-arterial chemotherapy for primary and metastatic brain cancer . Cancer Bull36:57-61, 1984
Ansfield FJ , Ramirez G., Skibba JL, et al: Intrahepatic arterial infusion with 5-fluorouracil. Cancer28:1147-1151,1971
52.
Stehlin JS, Hafstrom L., Greef PJ: Experience with infusion and resection in cancer of the liver. Surg Gynecol Obstet138:855-863, 1974
53.
Wellwood JM , Cady B., Oberfield RA: Treatment of primary liver cancer: Response to regional chemotherapy. Clin Oncol5:25-31, 1979
54.
Charnsangavej C., Chuang VP, Wallace S.: Transcatheter management of primary carcinoma of the liver. Radiology146:51-55,1983
55.
Patt YZ, Chuang VP, Wallace S.: Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. Cancer51:1359-1363, 1983
56.
Nevins JE, Hoffmann AA: Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. Am J Surg130:544-549,1975
57.
Ogata J., Migita N., Nakamura T.: Treatment of carcinoma of the bladder by infusion of the anticancer agent (mitomycin C) via the internal iliac artery. J Urol110:667-670,1973
58.
Wallace S., Chuang VP, Samuels ML, et al: Transcatheter intra-arterial infusion of chemotherapy in advanced bladder cancer. Cancer49:640-645, 1982
59.
Logothetis CJ, Samuels ML, Wallace S., et al: Management of pelvic complications of malignant urothelial tumors with combined intra-arterial and IV chemotherapy . Cancer Treat Rep66:1501-1507, 1982
60.
Logothetis CJ, Samuels ML, Selig DE, et al: Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors. Cancer Treat Rep69:33-38, 1985
61.
Logothetis CJ, Samuels ML: Intra-arterial chemotherapy for malignant urothelial tumors. Cancer Bull36:47-52, 1984
62.
Cromer JK, Bateman JC, Berry GN, et al: Use of intra-arterial nitrogen mustard therapy in the treatment of cervical and vaginal cancer. Am J Obstet Gynecol63:538-548, 1952
63.
Krakoff IH; Sullivan RD: Intra-arterial nitrogen mustard in the treatment of pelvic cancer . Ann Intern Med48:839-850,1958
64.
Sullivan RD , Wood AM, Clifford P., et al: Continuous intra-arterial methotrexate with simultaneous, intermittent intramuscular citrovorum factor therapy in carcinoma of the cervix. Cancer Chemother Rep8:1-6,1960
65.
Hulka JF, Bisel HF: Combined intra-arterial chemotherapy and radiation treatment for advanced cervical carcinoma. Am J Obstet Gynecol91:486-490, 1965
66.
Morrow CP, DiSaia PJ, Mangan CF: Continuous pelvic arterial infusion with bleomycin for squamous carcinoma of the cervix recurrent after radiation therapy. Cancer Treat Rep61:1403-1405, 1977
67.
Lifshitz S., Railsback LD, Buchsbaum HJ: Intraarterial pelvic infusion chemotherapy in advanced gynecologic cancer . Obstet Gynecol52:476-479, 1978
68.
Yamada K., Bremer AM, West CR, et al: Intraarterial BCNU therapy in the treatment of metastatic lung carcinoma. Cancer44:2000-2007,1979
69.
Swenerton KD , Evers JA, White GW, et al: Intermittent pelvic infusion with vincristine, bleomycin, and mitomycin c for advanced recurrent carcinoma of the cervix. Cancer Treat Rep63:1379-1381, 1979
70.
Kavanagh JJ : Regional chemotherapeutic approaches to the management of pelvic malignancies. Cancer Bull36:52-55, 1984
71.
Benjamin RS , Murray JA, Wallace S., et al: Intraarterial preoperative chemotherapy for osteosarcoma: A tool for prognostication facilitating limb salvage. Cancer Bull36:32-36, 1984
72.
Yap HY, Salem P., Hortobagyi GN, et al: Phase II study of cisdichlorodiammineplatinum (II) in advanced breast cancer. Cancer Treat Rep62:405-408, 1978
73.
Fleishman G. , Yap HY, Chuang VP, et al: Intrahepatic arterial combination sequential cis-diamminedichloroplatinum (II) and vinblastine for refractory metastatic breast carcinoma regionally confined to the liver. Proc Am Assn Ca Res23:148, 1982 (abstr)
74.
Yap HY, Fleishman G., Froschini G.: Intra-arterial infusion for liver metastases from breast cancer. Cancer Bull36:27-29, 1984
75.
Carlson JA, Freedman RS, Wallace S., et al: Intraarterial cisplatinum in the management of squamous cell carcinoma of the uterine cervix. Gynecol Oncol12:92-98, 1981
76.
Jaffe N., Wang H., Fellow KE, et al: Local en bloc resection for limb preservation. Cancer Treat Rep62:217-223,1978
77.
Patt YZ: Hepatic arterial chemotherapy for treatment and prophylaxis of liver metastasis from colon cancer. Cancer Bull36:21-26, 1984
78.
Patt YZ, Peters RE, Chuang VP, et al: Effective retreatment of patients with colorectal cancer and liver metastases. Am J Med75:237-240, 1983
79.
Patt YZ, Chuang VP, Wallace S., et al: The palliative role of hepatic artery infusion and arterial occlusion in colorectal carcinoma metastatic to the liver. Lancet1:349-351, 1981
80.
Patt YZ, Bedikian AY, Chuang VP, et al: New approaches to the treatment of Dukes' C colorectal carcinoma and metastatic colorectal carcinoma confined to the liver, in Stroehlein JR, Romsdahl MM (eds): Gastrointestinal Cancer. New York, NY, Raven, 1981, pp 391-403
81.
Patt YZ, Mavligit GM, Chuang VP, et al: Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): An effective treatment for metastatic colorectal carcinoma in the liver. Cancer46:261-265, 1980
82.
Ansfield FH , Ramirez G.: The clinical results of 5-fluorouracil intrahepatic arterial infusion in 528 patients with metastatic cancer to the liver. Prog Clin Cancer7:201-206, 1978
83.
Samuels ML, Moran ME, Johnson DE, et al: CISCA combination chemotherapy for metastatic carcinoma of the bladder, in Johnson, DE, Samuels ML (eds): Cancer of the Genitourinary Tract. New York, NY, Raven, 1979, pp 101-106
84.
Surbone A., Myers CE: Principles and practice of intraperitoneal therapy. Antibiot Chemother40:14-25, 1988 85. Laffer U., Knusli C., Harder F., et al: Intraperitoneal chemotherapy for gastrointestinal malignancies . Antibiot Chemother40:26-34, 1988
85.
Balis FM, Poplack DG: Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol11:74-86,1989
86.
Burch PA, Grossman SA, Reinhard CJ: Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study. JNCI80:1211-1216,1988
87.
Bleyer WA: Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep61: 1419-1425,1977
88.
Dinndorf PA , Bleyer WA: Management of infectious complications. of intraventricular reservoirs in cancer patients: Low incidence and successful treatment without reservoir removal. CancerDrug Deliv4:105-107,1987
89.
Lemann W., Wiley RG, PosnerJB: Leukoencephalopathy complicating intraventricular catheters: clinical radiographic and pathologic study of 10 cases. J Neurooncol6:67-74, 1988
90.
Giannone L. , Greco FA, Hainsworth JD: Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol4:68-73, 1986
91.
Hitchins RN , Bell DR, Woods RL, et al: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis . J Clin Oncol5:1655-1662,1987
92.
Yoshida T., Shimizu K., Mogami H., et al: Intrathecal ACNU for the treatment of a meningeal gliomatosis model. Gan To Kagaku Ryoho14:84-90, 1987
93.
Young GA, Milliken S., Jurd J., et al: The intraventricular reservoir in the treatment of neurological disease secondary to hematological malignancy: An eight year experience. Aust N Z J Med16:373-377,1988
94.
Boogerd W., vdSande JJ, Moffie D.: Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry51: 1277-1283,1988
95.
Werner RA: Paraplegia and quadriplegia after intrathecal chemotherapy. Arch Phys Med Rehabil69:1054-1056,1988
96.
Walker MC, Masters JR, Parris CN, et al: Intravesical chemotherapy: In vitro studies on the relationship between dose and cytotoxicity. Urol Res14:137-140, 1986
97.
Clausen HV, Brems-Dalgaard E.: An apparatus for intravesical chemotherapy. Ugeskr Laeger151:2084-2085, 1989
98.
Torti FM, Shortliffe LD, Williams RD, et al: Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group Study. J Clin Oncol6:476-483, 1988
99.
Mori K., Lamm DL, Crawford ED: A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: A South-West Oncology Group Study. Urol Int41:254-259,1986
100.
Novak R., Kern J., Fister H., et al: Effects of local chemotherapy and immunotherapy on the recurrence and progression of superficial bladder cancer. Eur Urol14:367-370,1988
101.
Guinan P., Richardson C., Hanna M., et al: BCG in the management of superficial bladder cancer. Prog Clin Biol Res303:447-453,1989
102.
Jaske G., Hofstadter F., Marberger H.: Topical doxorubicin hydrochloride therapy for carcinoma in situ of the bladder: A follow-up. J Urol131:41-42, 1984
103.
Jaske G., Hofstadter F., Marberger H.: Intracavitary doxcorubicin hydrochloride therapy for carcinoma in situ of the bladder. J Urol125:185-190, 1981
104.
Garnick MV , Schade D., Israel M., et al: Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma. J Urol131:43-46, 1984
Fukui I., Sekine H., Kihara K., et al: Intravesical combination chemotherapywith mitomycin-C and doxorubicin for carcinoma in situ of the bladder. J Urol141:531-534, 1989
107.
Zein TA, Friedberg N., Kim H.: Bone marrow suppression after intravesical mitomycin C Treatment. J Urol136:459-460,1986
